NLS Pharmaceutics and Kadimastem just scored a major win with a new Hong Kong patent covering IsletRx, a stem cell–based therapy designed to tackle insulin-dependent diabetes. Beyond the legal milestone, this development carries weight for patients, investors, and the broader medical field. Here are eight things you need to know.
- A New Patent in Asia
The Hong Kong Intellectual Property Department granted Kadimastem protection for its cell-selection and enrichment technology used in IsletRx. - Global IP Portfolio Strengthened
This patent adds to existing protections already secured in Europe, the United States, and India, building a global wall around the technology. - Why Hong Kong Matters
Hong Kong is not only a significant diabetes market but also a gateway into Mainland China and the Greater Bay Area, opening doors for future clinical collaborations. - Diabetes in Numbers
Roughly 706,000 adults in Hong Kong live with diabetes, representing about 8.2% of the adult population. Healthcare costs linked to the disease could hit $90 billion. - What Is IsletRx?
It’s a scalable platform designed to generate insulin-producing cells that mimic natural pancreatic islets, potentially restoring insulin regulation in patients. - Corporate Leaders Weigh In
NLS Pharmaceutics CEO Alexander Zwyer highlighted the strategic importance of Hong Kong in advancing the long-term goals of IsletRx. - Aiming for a Global Cure
Kadimastem’s CEO Ronen Twito emphasized that each new patent territory validates the technology and moves the company closer to clinical trials and patient access. - Hope Beyond Treatment
Unlike existing therapies that manage diabetes, IsletRx is being developed with the bold goal of curing the disease, not just controlling it.
With diabetes continuing to place a heavy economic and health burden worldwide, this patent marks another step toward a future where cell-based therapies could change lives.